Apple announces iPhone 17 with 48MP cameras and 6.3-inch display
COPENHAGEN - Genmab A/S (NASDAQ:GMAB), a $15.85 billion biotech company with an "EXCELLENT" InvestingPro financial health score, announced Wednesday that 92% of patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) successfully received their first full dose of epcoritamab in an outpatient setting, according to updated results from its Phase 2 EPCORE NHL-6 trial.
The study demonstrated the feasibility of treating and monitoring DLBCL patients outside of hospital settings while maintaining safety profiles consistent with previous epcoritamab studies. The findings were presented at the 13th Society of Hematologic Oncology Annual Meeting. With impressive gross profit margins of 94.5% and strong revenue growth of 33% over the last twelve months, Genmab continues to demonstrate robust operational execution.
Among the 81 patients treated as outpatients, 70% did not experience cytokine release syndrome (CRS) during the first full dose period. When CRS did occur, events were primarily low grade, with only 13.6% of patients requiring inpatient care.
The trial also showed efficacy in patients with limited prior treatment. Those who received epcoritamab after only one prior line of therapy (n=42) demonstrated a 64.3% overall response rate and a 47.6% complete response rate at a median follow-up of 5.8 months.
"The possibility of treating patients in the outpatient setting is encouraging and it may enable more people to have access to this treatment option across various sites of care, including community settings," said Jeff Sharman, Disease Chair of Hematology Research at Sarah Cannon Research Institute at Willamette Valley Cancer Institute.
DLBCL is the most common type of non-Hodgkin lymphoma worldwide, accounting for approximately 25-30% of all NHL cases, with about 25,000 new cases diagnosed annually in the U.S. According to InvestingPro analysis, Genmab appears undervalued at its current price of $25.89, with analysts maintaining positive outlook. The platform offers 11 additional exclusive ProTips and comprehensive financial analysis in its Pro Research Report, available to subscribers.
Epcoritamab is an IgG1-bispecific antibody designed to simultaneously bind to CD3 on T cells and CD20 on B cells to induce T-cell-mediated killing of CD20+ cells. The drug is being co-developed by Genmab and AbbVie as part of their oncology collaboration. With a P/E ratio of 11.66 and strong cash flows, Genmab maintains a solid financial position to support its development programs.
The safety and efficacy of epcoritamab for outpatient use in R/R DLBCL has not yet been approved by the FDA or other health authorities, according to the company’s press release statement.
In other recent news, Genmab A/S reported strong financial results for Q2 2025, with earnings per share reaching $0.542, a 39.4% increase over the forecasted $0.3888. The company also reported revenue of $925 million, which surpassed predictions by 3.54%. In addition to its earnings report, Genmab announced a slight increase in its share capital by 0.01% through the exercise of employee warrants, amounting to 4,563 shares. The new shares were subscribed in cash at varying prices. Furthermore, H.C. Wainwright raised its price target for Genmab A/S to $36 from $35, while maintaining a Buy rating on the stock. This adjustment reflects the firm’s analysis of upcoming catalysts, including a Phase 2 data update for acasunlimab expected in 2025. These developments highlight Genmab’s ongoing strategic and financial activities.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.